Maina Bhaman
Partner, Sofinnova Partners - Capital Strategy
Maina is a Partner in the Sofinnova Capital Strategy. She joined Sofinnova Partners in 2018, bringing an extensive network and a long track record as a healthcare investor.
Before Sofinnova, she was Director of Healthcare Investment at Touchstone Innovations in London. Earlier, she worked in the R&D teams of several biotech companies, including Celltech, Oxford GlycoSciences, Chimeric Therapies, and GeneMedicine.
"I've wanted to be in biotech since I was 16 years old," Maina said. "It was the early days, when Amgen and Genentech were first in the news, and it just sounded cool to me."
Her track record includes Myricx Bio, acquired by Novartis, and CinCor Pharma, acquired by AstraZeneca, Her current investments include Purespring Therapeutics, Sitryx Therapeutics, Mediar Therapeutics, Enyo Pharma, and Nuage Therapeutics.
Maina holds a BSc from the University of Texas at Austin and an MBA from Imperial College Business School.
“I've wanted to be in biotech since I was 16 years old. It was the early days, when Amgen and Genentech were first in the news, and it just sounded cool to me.”
Sectors
Biopharmaceuticals & Medical Devices
